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Abstract
Background: Human homeobox genes encode nuclear proteins that act as transcription factors involved in the
control of differentiation and proliferation. Currently, the role of these genes in development and tumor
progression has been extensively studied. Recently, increased expression of HOXB7 homeobox gene (HOXB7) in
pancreatic ductal adenocarcinomas (PDAC) was shown to correlate with an invasive phenotype, lymph node
metastasis and worse survival outcomes, but no influence on cell proliferation or viability was detected. In the
present study, the effects arising from the knockdown of HOXB7 in PDAC cell lines was investigated.
Methods: Real time quantitative PCR (qRT-PCR) (Taqman) was employed to assess HOXB7 mRNA expression in 29
PDAC, 6 metastatic tissues, 24 peritumoral tissues and two PDAC cell lines. siRNA was used to knockdown HOXB7
mRNA in the cell lines and its consequences on apoptosis rate and cell proliferation were measured by flow
cytometry and MTT assay respectively.
Results: Overexpression of HOXB7 mRNA was observed in the tumoral tissues and in the cell lines MIA PaCa-2 and
Capan-1. HOXB7 knockdown elicited (1) an increase in the expression of the pro-apoptotic proteins BAX and BAD in
both cell lines; (2) a decrease in the expression of the anti-apoptotic protein BCL-2 and in cyclin D1 and an increase
in the number of apoptotic cells in the MIA PaCa-2 cell line; (3) accumulation of cell in sub-G1 phase in both cell
lines; (4) the modulation of several biological processes, especially in MIA PaCa-2, such as proteasomal ubiquitin-
dependent catabolic process and cell cycle.
Conclusion: The present study confirms the overexpression of HOXB7 mRNA expression in PDAC and demonstrates
that decreasing its protein level by siRNA could significantly increase apoptosis and modulate several biological
processes. HOXB7 might be a promising target for future therapies.
Keywords: Pancreatic ductal adenocarcinoma, Homeobox, HOXB7, siRNA, Gene expression
Background
PDAC is one of the most frequent causes of cancer-related
death worldwide. It is an aggressive neoplasia whose early
diagnosis and treatment are challenging, making it a lead-
ing cause of death by cancer [1]. Most patients are diag-
nosed at an advanced stage and only a few of these pa-
tients are suitable candidates for curative surgery [2,3].
Homeobox-containing genes encode DNA-binding pro-
teins that regulate gene expression and control various as-
pects of morphogenesis and cell differentiation [4]. In
humans, HOX genes are represented by 39 members classi-
fied in four groups (HOX-A, HOX-B, HOX-C and HOX-D)
located on chromosomes 7p, 17q, 12q and 2q, respectively.
Aberrant expression of homeobox genes have been shown
in different tumour types [5-9], including leukemias [10,11],
ovarian carcinoma [12], and breast cancer [13]. The gene
expression of HOXB5, HOXB6, HOXC8 and HOXD13 have
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already been characterized in pancreatic cancer [14].
HOXB7 has an important role in various tumors. In mela-
nomas, overexpression of HOXB7 constitutively activates
basic fibroblast growth factor (bFGF), favoring uncontrolled
cell proliferation [15]. In a breast cancer cell line (SkBr3),
transduction of HOXB7 gene induces bFGF expression, in-
creases growth rate and ability of cells to form colonies in
semisolid medium [16]. In addition to bFGF, HOXB7 can
also induce the expression of other genes, especially those
related to angiogenesis and tumor invasion including vas-
cular endothelial growth factor (VEGF), interleukin-8,
angiopoietin-2, and metalloproteases 2 and 9 [17]. In-
creased expression of HOXB7 was also described in oral
squamous cell carcinoma, where it induces cell proliferation
and has been shown to be associated with poor prognosis
[18]. In colorectal cancer, the protein encoded by HOXB7
was considered as a prognostic factor and mediator of
tumor development and progression [19]. Recently HOXB7
status was investigated in a large cohort of PDAC, the au-
thors observed overexpression of HOXB7 and its correl-
ation with invasive phenotype, lymph node metastasis and
worse survival outcomes, but no influence on cell prolifera-
tion or viability was detected [20]. The aim of this study
was to further investigate HOXB7 expression in PDAC and
metastatic tissues in comparison to normal pancreatic and
peritumoral tissues as well as to evaluate the effects of
HOXB7 knockdown in pancreatic cancer cell lines, address-
ing cell proliferation, apoptosis and gene expression profile.
Methods
Patients and tumor characterization
Tissue collection was carried out in compliance with The
Ethical Committee of Hospital das Clínicas (Faculdade de
Medicina da Universidade de São Paulo) and in accordance
to The Declaration of Helsinki, with informed and free con-
sent obtained from each subject. The following tissue sam-
ples were obtained from patients diagnosed with PDAC:
tumoral (n=29), disease-free tissues (located distant from
the tumor site, n=24) and metastatic tissues (liver metasta-
sis, n=6). Ten normal pancreatic tissue samples obtained
within 8 hours post-mortem from subjects without pancre-
atic diseases were used as control. The diagnosis was
established by clinical, biochemical, and radiological find-
ings and supported by the anatomopathological analysis of
tumor samples.
During surgical procedure, tumor fragments were col-
lected in sterile containers with 1 mL of RNAlater®
(Ambion, Inc., Austin, TX, USA) and stored at 4°C. All tu-
moral, disease-free and metastatic samples were resected
by a experienced surgeon.
RNA and DNA extraction
The material collected in RNAlater® (Ambion) was
fragmented in a tissue pulverizer (Mikro-Dismembrator U,
B. Braun Biotech International, Melsungen, Hesse,
Germany). Total RNA was extracted from approximately
100 mg tissue after homogenization, using with RNeasy Plus
Mini Kit (Qiagen, Duesseldorf, North Rhine-Westphalia,
Germany) according to manufacturer’s guidelines. DNA was
extracted using the DNeasy kit (Qiagen) according to the
manufacturer’s instructions.
Both were measured spectrophotometrically being
adopted values of optical density 260/280 nm and 260/230
nm between 1.8 and 2.0. A integrity of RNA was checked
by visual inspection of the 18S e 28S ribosomal RNA bands
in 1% agarose gel, while DNA integrity was verified by the
presence of a single band in agarose gel 2%.
Validation of endogenous reference gene
In order to determine the most stable gene and to
normalize the target gene in pancreatic tissues, we studied
the expression of 32 commonly used reference genes. The
expression of candidate genes was evaluated with the
TaqMan Express Endogenous Control Plate, according to
the manufacturer’s protocol (Applied Biosystems, Foster
City, CA, USA). The genes are performed in triplicate in
these arrays and are constitutively expressed at moderate
abundance across most test samples. cDNA was prepared
from ten samples of normal pancreatic tissue and ten sam-
ples of PDAC using SuperScript™ III Reverse Transcriptase
(Invitrogen Corporation, Carlsbad, CA, USA). Gene expres-
sion was measured by quantitative real time qRT-PCR and
expression stability was analyzed with geNorm [21] and
NormFinder [22]. Based on the results of this analysis,
RPL30 was proposed as the most appropriate control gene
(Figure 1).
Quantitative real-time polymerase chain reaction after
reverse transcription (qRT-PCR)
Complementar DNA (cDNA) was synthesized from total
RNA extracted from each cell line and tissue samples.
Briefly, first-strand cDNA synthesis used 1 μg of total
RNA, 1 μL of oligo(dT) primers (0.5 μg/μL), 1 μL of a
solution of all four deoxyribonucleoside triphosphates
(each at 10 mM), and 10× SuperScript™ III Reverse
Transcriptase (Invitrogen Corporation). For TaqMan-
based qRT-PCR, 50 ng of cDNA was added to 10 μL of
2× Taqman Universal PCR Master Mix (Applied
Biosystems) and 1 μL of 20× HOXB7 primers and the
probe set (Applied Biosystems). The one-step RT-PCR
was performed using a StepOne Plus (AB Applied
Biosystems) for an initial 2 minutes incubation at 50°C,
10 minutes incubation at 95°C followed by 40 cycles of
PCR 95°C for 15 seconds and 60°C for 1 minute. Data
values (Cycle Threshold [Ct] values) were extracted from
each assay with the SDS v2.0 software tool (Applied
Biosystems).
Chile et al. BMC Cancer 2013, 13:451 Page 2 of 12
http://www.biomedcentral.com/1471-2407/13/451
The number of specific (HOXB7) transcripts in tumor
samples was normalized to housekeeping gene RPL30
mRNA in three independent experiments. Glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) was used as denomi-
nators of gene expression in cell lines. Gene expression
levels were analyzed by the comparative Ct method (ΔΔCt)
[23].
Copy number analysis of HOXB7 by real-time quantitative
PCR (qPCR)
HOXB7 amplification was assessed by qPCR using Plat-
inum® SYBR® Green qPCR SuperMix-UDG (Invitrogen
Corporation). Beta-2-microglobulin (β2M) was used as
reference gene for the evaluation of HOXB7 copy
number.
Genomic DNA (100 ng/μL) from each tissue sample was
conducted on a Applied Biosystems StepOne Plus (Applied
Biosystems, Foster City, CA, USA) using the following
primers for genomic sequences of HOXB7 (sense: 5′- CGA
TGC AGG GCT TGT ACC -3′; anti-sense: 5′- AGG CGC
CTT CAG GGTAAT −3′) and β2M (sense: 5′- CGT GTG
AAC CAT GTG ACT TTG −3′; anti-sense: 5′- GAA TTC
ATC CAA TCC AAA TGC −3′). The reaction was incu-
bated for 5 minutes at 94°C, followed by 40 cycles of 30
seconds at 94°C, 30 seconds at 55°C, and 90 seconds at
72°C, with a final extension of 72°C for 7 minutes. All
samples were run in duplicate and positive HOXB7 gene
amplification was defined as a copy number of > 3 [24].
Cell culture
Human pancreatic cancer cell line MIA PaCa-2 was
obtained from American Type Culture Collection (ATCC®
Number: CRL-1420™, Manassas, VA, USA). The cells were
maintained routinely in Roswell Park Memorial Institute
(RPMI) 1640 medium (Invitrogen Corporation, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum
(FBS, Invitrogen Corporation), 100 U/mL penicillin G
(Invitrogen Corporation), and 0.1 mg/mL streptomycin sul-
fate (Invitrogen Corporation) at 37°C in a humidified, 5%
CO2, 95% air atmosphere. Capan-1 cell line established
from a hepatic metastasis of a PDAC was also obtained
from ATCC (Number: HTB-79™). The cells were grown in
IMDM medium (Invitrogen Corporation) supplemented
with 20% FBS (Invitrogen Corporation).
RNAi knockdown (siRNA) and transfection
The human pancreatic cancer cell lines were cultured as
described. siRNA and transfections were performed fol-
lowing the manufacturer’s protocols of the TriFECTa
Dicer- Substrate RNAi kit (IDT, Coralville, IA, USA) and
Lipofectamine RNAi Max Reagent (Invitrogen Corpor-
ation). 105 cells were plated in 6-well in RPMI medium
one day prior to transfection. Cells were transfected with
Figure 1 RPL30 gene showed the least variation of expression among all tested housekeeping genes in samples from normal
pancreatic tissue and pancreatic ductal adenocarcinomas.
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a nonspecific scrambled siRNA and with a HOXB7-spe-
cific siRNA at a final concentration of 10 nM. The
mRNA content was measured 48 hours after transfec-
tion. All transfections were minimally performed in du-
plicate. HOXB7 depletion and RT-qPCR were performed
as described above. Each experiment was repeated at
least twice.
Western blotting
After 48 h electroporation with siRNAs, cells were homog-
enized in RIPA buffer (Cell Signaling Technology, Danvers,
MA, USA) with protease inhibitors (Complete, Mini,
EDTA-free Protease Inhibitor Cocktail Tablet, Roche Ap-
plied Science, Penzberg, Upper Bavaria, Germany). The
homogenate was centrifuged at 16,700 g for 30 minutes at
4°C. Protein concentration was measured using Lowry
method [25].
Thirty micrograms of total protein was separated on a
14% sodium dodecyl sulfate polyacrylamide gel followed
by transfering to an Immobilon-P membrane (Merck
Millipore, Billerica, MA, USA). Membranes were incu-
bated for 18 hours in 5% skim milk phosphate buffer sa-
line (PBS) with mouse monoclonal antibody HOXB7
(1:50, ab51237, Abcam Inc, Cambridge, MA, USA)
followed by incubation with secondary antibody (1:400,
RPN1001, GE Healthcare, Little Chalfont, Buckingham-
shire, UK) and labeled with horseradish peroxidase
(1:3000, GE Healthcare). Rabbit anti-beta actin antibody
(1:1000, ab8227, Abcam Inc, Cambridge, MA, USA) was
used as internal control. Photographic film was exposed
to the membrane in a dark room.
MTT cell proliferation assay
Cell proliferation was evaluated after 24 hours, 48 hours
and 72 hours after transfection with siRNA-HOXB7 using
a specific colorimetric assay. In particular, cells were ex-
posed to HOXB7 siRNA and then stained with 3-(4,5-
dimethylthiazol-2-yl) – 2,5-diphenyltetrazolium bromide
(MTT, Sigma-Aldrich, St Louis, MO, USA). The absorb-
ance was measured by ELx 808 Ultra Microplate Reader
(Bio-Tek Instruments, Inc, Winooski, VT, USA) at a wave-
length of 570 nm.
Flow cytometry – markers, cell cycle distribution, and
apoptosis analysis
Forty-eight hours after transfection, the human pancre-
atic cells lines were trypsinized and inactivated with FBS,
centrifuged at 1,500 rpm for 10 min, and the super-
natant was discarded. The pellet was resuspended in 5
mL of PBS at a concentration of 106 cells/mL. To
analyze intracytoplasmic and nuclear markers, cells were
permeabilized with 5 μL of 0.1% Triton X-100 for 30
min before the addition of specific primary antibodies.
The following markers were used to determine cell
death pathways: Bax (Ab5714, Abcam Inc), Bad
Ab32445, Abcam Inc), and Bcl-2 (Ab692, Abcam Inc).
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Figure 2 Relative expression levels of HOXB7 mRNA. Panel A depicts normalized expression values in pancreatic tissues. The horizontal line
within the box plot represents the median value, the box plot limits refer to 25th to 75th percentiles, and the box plot bars include the 10th to
90th percentiles. Panel B indicates normalized expression values in pancreatic cell lines (MIA PaCa-2 and Capan-1) and pool of normal tissues. The
experiments were carried in triplicate and are represented as mean ± standard deviation *p= 0,01.
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Antibodies for cyclin D1 (sc8396, Santa Cruz Biotech-
nology Inc, Santa Cruz, CA, USA) were used to deter-
mine the proliferation index. The samples were analyzed
in a flow cytometer (FACSCalibur, BD, Franklin Lakes,
NJ, USA), and expression of cell proliferation and cell
death markers were compared with parental control
cells.
Detection of the markers was followed by analysis of
the cell cycle phases. In this step, the trypsinized cells
were treated with 70% ice-cold ethanol containing 100
μg/mL RNase. They were then washed and incubated in
PBS at 37°C for 45 minutes. The labeling was performed
in a solution containing propidium iodide (PI) at a con-
centration of 1.8 mg/mL to assess the integrity and
quantity of DNA in the cell cycle phases.
Evaluation of apoptosis was carried out using Annexin
V FITC Apoptosis Detection kit I (BD) according to the
manufacturer’s instructions. Cells were centrifuged and
the cell pellet was suspended with binding buffer
(100 μL) and then incubated with Annexin V-FITC (2 μL)
Figure 3 HOXB7 gene copy number detected by quantitative PCR in pancreatic tissues and two cell lines. Positive amplification was
defined as ≥ 3 copies. N- normal pancreas; PDA- pancreatic ductal adenocarcinoma; M- metastatic tissue.
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and PI (2 μL) for 15 minutes, at room temperature in the
dark. After incubation, 400 μL of binding buffer was
added and cells were analyzed in a FACScalibur (BD)
using CellQuest software for determining the percentage
of apoptotic cells. A minimum of 10,000 events was ac-
quired for each sample [26].
Microarray analysis after knockdown of HOXB7
Total RNA derived from the inhibition of gene transcript
HOXB7 as well as from parental cells were quantified in
Bioanalyzer (Agilent, Santa Clara, CA, USA). This pro-
cedure was performed in duplicate for all cell lines,
which were sorted into treated and untreated with
Figure 4 HOXB7 gene expression 48 hours after transfection of siRNA. Panel A depicts relative expression levels of HOXB7 mRNA in MIA
PaCa-2 (*p=0.0270) and Capan-1 (*p=0.0003) cells lines; the experiments were carried in triplicate and are represented as mean ± standard
deviation. Panel B depicts HOXB7 protein expression; beta-actin was used as internal control. NC- negative control.
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Figure 5 Colorimetric assay for cell viability (MTT). The results represent the mean ± standard error of three independent experiments and
are presented after normalizing to the respective controls. No significant decreases in cell viability were observed after 24, 48 and 72 hours of
HOXB7 siRNA treatment in MIA PaCa-2 or Capan-1 cell lines.
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siRNA. Each reaction was prepared from 200 ng of total
RNA in a volume of 1,5 μL. The guidelines of the proto-
col One-Color Microarray-Based Gene Expression
(Agilent, Santa Clara, CA, USA) were followed with the
use of Agilent Low Input Quick Amp Labeling Kit. Hy-
bridized slides (Human 4x44K Microarray) were washed
as recommended and scanned using the High-
Resolution Microarry Scanner (Agilent, Santa Clara, CA,
USA). Data were extracted with Agilent Technologies
Feature Extraction Software version 9.5.3.
Validation of microarray assay
Validation of microarray was performed from the ana-
lysis of E2F and RB1 mRNA expression in Mia PaCa-2
cell line by RT-qPCR. The experiment was performed as
described previously.
Statistical analysis
For analysis of HOXB7 expression and amplification statis-
tical tests were two-tailed, with statistical significance fixed
at 0.05. Continuous variables were analyzed using Kruskal-
Wallis and Mann–Whitney U nonparametric tests. Values
were expressed as median, minimum and maximum values.
Data were analyzed using JMP Software version 8 (SAS In-
stitute Inc, Cary, NC, USA).
Statistical analysis of MTT and flow cytometry was
performed by analysis of variance (ANOVA) with the mul-
tiple comparison test of Tukey-Kramer. Values were
Figure 6 BCL-2, BAD, BAX and D1 cyclin expression as evaluated by flow cytometry. Panels A and B demonstrate MIA PaCa-2 and Capan-1
cells lines, respectively. The experiments were carried out in triplicate and the bars represent mean ± standard deviation. NC- negative control.
* p <0.05, ** p <0.01, *** p <0.001.
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expressed as mean ± standard deviation, considering as sig-
nificant p values < 0.05.
Analysis of data obtained from the microarray experi-
ment was performed using the self-HT [27]. The self-self
experiments were performed with duplicates untreated la-
beled with Cy3 (untreated lineage x untreated lineage), as-
suming, then, that the variability of signal in microarray
experiments is dependent of the intensity and any differ-
ence in hybridization is product of experimental artifact.
From the self-self, a credibility interval of 99% was
established to differentiate changes in expression of tech-
nique artifact, resulting therefore in determining intensity-
dependent cutoffs, which were used in the experiments
non-self-self (treated lineage x untreated lineage). On the
platform array, the same gene is shown more than once by
different probes, therefore, three criteria have been defined
for identifying genes differentially expressed: (1) each gene
was represented by at least two probes; (2) more than 50%
of the probes representing one particular gene presented
signal after expression quality analysis; (3) there was 100%
agreement between the probe signal (up regulation or down
regulation). Microarray data are available through the
Minimum Information About a Microarray Experiment
(MIAME, accession number GSE46393).
Two lists of differentially expressed genes were generated
for each cell line, one containing the upregulated genes and
other presenting downregulated genes common to the ex-
perimental duplicates. Each list was annotated in categories
of biological processes according to the Gene Ontology
database and the analysis was performed in WebGestalt
[28]. The results were seen in directed acyclic graphs to
maintain the relationship between categories enriched.
Hypergeometric test was used to evaluate the categor-
ical enrichment and as multiple categories were tested
simultaneously, p values were adjusted according to the
adjustment method of multiple test proposed by
Figure 7 Distribution of cell cycle phases as evaluated by flow cytometry. Panels A and B represent MIA PaCa-2 and Capan-1 lines,
respectively. **p<0.01; ***p<0.001.
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Benjamini and Hochberg [29]. The significance for en-
richment analysis was fixed at 0.01. Furthermore, a mini-
mum number of two genes were established as the
cutoff required.
Results
HOXB7 mRNA expression in pancreatic tissue samples
and cell lines
HOXB7 mRNA expression was analyzed in 29 pancreatic
ductal adenocarcinoma samples, 24 peritumoral tissue
samples, 6 metastatic tissues samples, and 10 normal
pancreatic tissue samples. A higher content of HOXB7
mRNA was observed in tumoral and in metastatic tis-
sues in comparison to normal pancreas (control)
(Figure 2A). HOXB7 mRNA overexpression was also ob-
served in MIA PaCa-2 and Capan-1 cell lines
(Figure 2B).
The number of copies of HOXB7 was determined in
all tissue samples and in both cell lines with the purpose
of investigate the possibility of genomic amplification.
As shown in Figure 3, only two tumoral samples and the
Capan-1 cell line presented more than three copies of
HOXB7 gene.
HOXB7 silencing evaluation
The two human pancreatic cell lines MIA PaCa-2 and
Capan-1 were transiently transfected with two siRNA
duplexes targeting different encoding regions of human
HOXB7 mRNA, named as siRNA1 and siRNA2 or a
nonspecific scrambled siRNA control. After 48 hours,
the HOXB7 mRNA and protein levels were quantified by
real time RT-PCR and western blot, respectively. HOXB7
siRNA significantly silenced the content of HOXB7
mRNA in both pancreatic cell lines while the scrambled
siRNA had no effect (Figure 4A). Approximately 96%
and 65% of HOXB7 mRNA were silenced in MIA PaCa-
2 and Capan-1 cells, respectively. Western Blotting ana-
lysis also demonstrated that HOXB7 siRNAs decreased
proteins level in both cell lines (Figure 4B).
MTT assay
The impact of siRNA transfection on cell viability was
investigated after 24, 48, and 72 hours of incubation,
using the MTT assay. As shown in Figure 5, no signifi-
cant differences in absorbance were observed in com-
parison to the parental cells.
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Figure 8 Percentage of apoptotic cells as evaluated by flow
cytometry after treatment with siRNA against to HOXB7. The
bars represent mean ± standard deviation. NC- negative control.
* p <0.05.
Table 1 Biological processes associated with HOXB7
transcript inhibition in MIA PaCa-2 cell lineage
Biological process
Cellular macromolecular complex
assembly
C=336;O=32;E=13.19;R=2.43;
rawP=3.34e-06;adjP=0.0012
Macromolecular complex subunit
organization
C=741;O=55;E=29.09;R=1.89;
rawP=3.63e-06;adjP=0.0012
Macromolecular complex assembly C=672;O=51;E=26.38;R=1.93;
rawP=4.49e-06;adjP=0.0012
Organelle organization C=1339;O=87;E=52.57;R=1.66;
rawP=1.38e-06;adjP=0.0012
Cellular macromolecular complex
subunit organization
C=396;O=36;E=15.55;R=2.32;
rawP=2.42e-06;adjP=0.0012
Protein complex assembly C=520;O=42;E=20.41;R=2.06;
rawP=7.28e-06;adjP=0.0014
Protein complex biogenesis C=520;O=42;E=20.41;R=2.06;
rawP=7.28e-06;adjP=0.0014
Cellular protein complex assembly C=184;O=21;E=7.22;R=2.91;
rawP=1.12e-05;adjP=0.0019
Proteasomal ubiquitin-dependent
protein catabolic process
C=107;O=15;E=4.20;R=3.57;
rawP=1.79e-05;adjP=0.0022
Proteasomal protein catabolic
process
C=107;O=15;E=4.20;R=3.57;
rawP=1.79e-05;adjP=0.0022
Interspecies interaction between
organisms
C=280;O=27;E=10.99;R=2.46;
rawP=1.56e-05;adjP=0.0022
Cell cycle C=895;O=60;E=35.14;R=1.71;
rawP=2.98e-05;adjP=0.0033
Amine biosynthetic process C=78;O=12;E=3.06;R=3.92;
rawP=4.83e-05;adjP=0.0050
Positive regulation of ubiquitin-
protein ligase activity
C=67;O=11;E=2.63;R=4.18;
rawP=5.37e-05;adjP=0.0052
Positive regulation of ligase activity C=70;O=11;E=2.75;R=4.00;
rawP=8.13e-05;adjP=0.0073
Chromatin organization C=364;O=30;E=14.29;R=2.10;
rawP=0.0001;adjP=0.0084
C- Reference genes in the category, O- number of genes in the gene set and
also in the category, E- expected number in the category, R- ratio of
enrichment, rawP- p value from hypergeometric test, adjP- p value adjusted
by the multiple test adjustment.
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Flow cytometric analyses of markers of proliferation and
cell death
Modulation of BAX, BAD (pro-apoptotic), BCL-2
(antiapoptotic) and D1 cyclin (marker of cell prolifera-
tion) were evaluated after 48 hours of treatment with
HOXB7 siRNA. An increased in the expression of the
pro-apoptotic proteins BAX and BAD was observed in
both cell lines (p<0.01), while expression of BCL-2 and
cyclin D1 were significantly decreased by treatment in
MIA PaCa-2 cell line (p<0.01 and p<0.05 respectively)
(Figure 6A). In the Capan-1 cell line, there was an in-
crease in the expression of the pro-apoptotic BAX and
BAD proteins (p<0.01 and p<0.05, respectively), but
BCL-2 and D1 cyclin expression remained unchanged
after treatment (Figure 6B).
Cell cycle distribution was assessed after staining fixed
cells with PI and thereby cells in different phases of cell
cycle were discriminated: G1, S, G2/M; siRNA-
transfected cell lines vs. scrambled control and parental
demonstrated an accumulation of cells in sub-G1 phase
in MIA PaCa-2 (Figure 7A) and Capan-1 (Figure 7B).
The process of apoptosis was assessed 48 hours after
inhibition of HOXB7 mRNA in the two cell lines stud-
ied; only MIA PaCa-2 cell line demonstrated an increase
in the percentage of apoptotic cells after treatment
(Figure 8).
Effects of HOXB7 silencing in gene expression profile of
PDAC cell lines
In MIA PaCa-2, 679 genes were identified as
downregulated after HOXB7 silencing in comparison to
parental cells. The genes were grouped into different cat-
egories according to the biological process (Table 1). On
the order hand, 12 genes were downregulated and 96 were
upregulated in treated Capan-1 cell line compared to
parental cells, which were not grouped due to the
established statistical cut.
Downregulation of E2F and RB1 genes in MIA PaCa-2
after HOXB7 silencing
Among the downregulated genes in MIA PaCa-2 after
inhibition of HOXB7, we validated the RB1 and E2F
transcript expression. As shown in Figure 9, the two
downregulated genes were confirmed by quantitative
real time PCR.
Discussion
The main findings of the present study was confirmation
of HOXB7 mRNA overexpression in PDAC as well as
the demonstration that its knockdown in two human
PDAC cell lines increases expression of the pro-
apoptotic proteins BAX and BAD, elicits an accumula-
tion of cells in the sub-G1 phase and modulates cellular
gene expression profile.
Nguyen et al. [20] have previously demonstrated
overexpression of HOXB7 mRNA in PDAC, which was
positively correlated with lymph node metastasis and
considered a predictor of poor prognosis. In that study,
knockdown of HOXB7 by siRNA in the pancreatic cell
lines BxPC3, MIA PaCa-2 and PANC1 resulted in de-
creased invasion but it did not influence cell prolifera-
tion or viability as evaluated by the MTT assay [20].
This latter result was also observed in the present study,
concomitantly with increased apoptosis as evaluated by
flow cytometry in MIA Paca-2 cell line. These apparent
discrepant results between the MTT assay and flow cy-
tometry may reflect limitations of the MTT assay, since
the metabolic activity measured by this methodology
may be changed by different conditions or chemical
treatments [30].
Knockdown of HOXB7 mRNA promoted an increase
in the expression of the pro-apoptotic BAD and BAX
proteins in both studied cell lines, but the pattern of ex-
pression of the anti-apoptotic BCL2 protein differed be-
tween them: in MIA PaCa-2, there was a reduction in
BCL2 expression, while no significant changes were
detected in the Capan-1 cell line. Additionally,
downregulation of cyclin D1 also took place only in
MIA PaCa-2 cells. The sum of these events may explain
the increased apoptosis induced by HOXB7 siRNA only
in MIA Paca-2 cell line.
MIA PaCa-2 and Capan-1 cell lines are derived from
pancreatic cancer and we have evaluated both because
the first was established from a primary tumor [31]
while Capan-1 derived from a hepatic metastasis [32].
They are known to present distinct phenotypic and
genotypic characteristics, such as adhesion, invasion, mi-
gration, and expression status of commonly altered
genes (KRAS, p53, p16, and SMAD4) [33]. Thus, it is
Figure 9 Validation of microarray assay by qRT-PCR. RB1 and
E2F gene relative expression 48 hours after transfection of HOXB7-
specific siRNA. The experiments were carried in triplicate and are
represented as mean ± standard deviation *p <0,05.
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not surprising that these cell lines may exhibit distinct
behaviors, as already described in other experimental
conditions [33].
According to Hyman et al. gene amplification may be an
important mechanism underlying the increased expression
of HOXB7 in breast cancer. However, gene amplification
was detected in only 10% of the tested samples [34]. The
analysis of HOXB7 gene copy number in the present study
suggests that its increased expression in PDAC does not re-
sult from gene amplification, which was identified in only
two tumoral samples and in the Capan1 cell line. It is pos-
sible that overexpression of HOXB7 is linked to epigenetic
events, which have already been described for other HOX
family members [35].
Regardless of the mechanism by which HOXB7 mRNA
expression is upregulated in PDAC, we have demon-
strated that its knockdown increases apoptosis and also
modulates several biological processes only in MIA
PaCa-2. Some of the identified biological processes were
already described as affected by HOX genes in other cell
types. For instance we have observed downregulation of
genes belonging to proteasomal ubiquitin-dependent
catabolic protein process whereas Wang et al. [36]
reported that upregulation of HOXA10 in myeloid cells
enhances the protein-dependent ubiquitination of the
ubiquitin ligase Triad-1.
We have also shown that suppression of HOXB7 mainly
caused an imbalance in the cell cycle, especially in MIA
PaCa-2 cell line, which presented not only downregulation
of genes associated with cell cycle in the microarray, but
also a reduction of expression of Cyclin D1 in the flow cy-
tometry analysis. This event was also reported by Liao et al.
[19], who detected downregulation of cyclin D1 and up-
regulation of p27 after HOXB7 gene silencing with conse-
quent blocking G1-S. Here, we showed E2F and retinoblast-
oma B1 (RB1) wich are essential for the G1-S transition.
These downregulated transcripts were identified by micro-
array and confirmed by quantitative real time PCR.
Understanding the molecular abnormalities involved
in the pathogenesis of PDAC may reveal new targets for
therapy and inhibition of mRNA expression mediated by
siRNA can be used to unravel the role of specific genes
in the tumorigenic process. In this sense, in the present
study, the inhibition of HOXB7 expression in MIA
PaCa-2 and Capan-1 cell lines corroborated the partici-
pation of this homeobox gene in the development of
PDAC, reinforcing the need for further investigation.
Although the chemotherapeutic agent gemcitabine
represents the standard for pancreatic cancer treatment,
its use is far from ideal, as prolonged exposure leads to
drug resistance. This is a major cause of treatment fail-
ure for pancreatic adenocarcinoma and novel thera-
peutic approaches are needed [37,38]. The use of RNA
interference as a therapeutic modality has generated
great expectations, however, finding a way to efficiently
deliver it to cancer cells is challenging. The inhibition of
HOXB7 by RNA interference in PDAC could be a prom-
ising target to be used in combination with conventional
chemotherapy.
Conclusions
HOXB7 is overexpressed in pancreatic adenocarcinomas
and in the two studied pancreatic cell lines; the siRNA
assay suggests that HOXB7 is involved in pancreatic cell
proliferation and apoptosis. HOXB7 is another compo-
nent of the extensive network of molecules involved in
the pathobiology of pancreatic cancer and might consti-
tute a promising target for future biological therapies.
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